Ironwood sees FY26 revenue $450M-$475M, consensus $319.47M

TipRanks

Sat, January 3, 2026 astatine 6:20 AM CST 1 min read

Sees FY26 adjusted EBITDA greater than $300M. “In 2026, we stay focused connected our halfway priorities of maximizing LINZESS, advancing apraglutide and delivering sustained profits and currency flows. We judge our full-year 2026 guidance demonstrates the important advancement we’ve made to present connected these priorities to assistance thrust worth for shareholders moving forward. Effective January 1, 2026, the LINZESS database terms has been lowered successful effect to evolving wellness attraction dynamics and to enactment ongoing diligent access. In turn, we expect higher nett income successful 2026 for LINZESS year-over-year, specifically driven by the elimination of the inflationary constituent of statutory required rebates crossed channels, including Medicaid, owed to the alteration successful database price. In conjunction with the anticipated accrued nett sales, we expect our continued absorption connected disciplined disbursal absorption to effect successful greater than $300 cardinal successful adjusted EBITDA successful 2026. Finally, we proceed to advancement our antecedently announced strategical alternatives reappraisal successful an effort to maximize shareholder worth and look guardant to providing further updates arsenic appropriate,” added Tom McCourt.

• Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions

• Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential